OTC$ZOMDF
Zomedica Corp · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Revenue increased by 14% to $6.3 million, gross margin was 66%, and liquidity reached $91 million.
Zomedica reported a strong first quarter in 2024, with revenue up 14% to $6.3 million compared to the same period last year. The company's gross margin was 66%, and it maintained a solid liquidity position with $91 million in cash, cash equivalents, and available-for-sale securities.
- Revenue for Q1 2024 grew 14% to $6.3 million, driven by growth in Therapeutic Devices and Diagnostics segments.
- Gross margin was 66% for the first quarter of 2024.
- Total cash used during the quarter was $9.6 million, with a non-GAAP operating burn of approximately $4.4 million when adjusted for non-recurring one-time items.
- The company continues to expect full-year revenue in the range of $31 to $35 million.
Headline financials
Revenue & EPS history
Zomedica · Revenue · Quarterly
$6.26M
Revenue by segment
Zomedica · $6.96M total across 2 segments · Q2 2025
- Therapeutic Devices$6.18M—88.8%
- Diagnostics$781K—11.2%
Forward guidance
The Company continues to expect full year revenue in the range of $31 to $35 million.
Tailwinds
- Growth in 2024 will be driven by its existing portfolio, including recently launched products.
- Supported by investments the Company is making to continue to drive increased adoption and utilization of its products.
- Contributions from a number of new products that the Company expects to launch during 2024.
- Revenues should increase sequentially from the first quarter.
- Majority of revenue expected to be recorded during the back half of the year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
-1.2%
Avg return
Earnings day
+2.3%
Avg return
5 days after
-1.6%
Avg return
30 days after
27%
9 / 33 earnings
Positive
+41.0%
Q4 2024
Best reaction
-16.9%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -8.2% | -4.0% | -5.1% | |
| Q3 2025 | +1.3% | +26.3% | +50.0% | |
| Q1 2025 | -16.9% | -20.3% | -22.0% | |
| Q4 2024 | +41.0% | +113.9% | +41.7% | |
| Q3 2024 | -1.4% | +14.8% | +3.3% | |
| Q2 2024 | -5.3% | -11.6% | -14.8% | |
| Q1 2024 | -16.8% | -11.0% | -9.1% | |
| Q4 2023 | -4.0% | -4.1% | -2.7% | |
| Q3 2023 | -4.4% | -7.2% | -6.7% | |
| Q2 2023 | -2.3% | -3.9% | -12.2% | |
| Q1 2023 | -8.8% | -8.2% | -10.5% | |
| Q4 2022 | -4.3% | -16.5% | -10.7% | |
| Q3 2022 | -5.3% | -10.0% | -19.6% | |
| Q2 2022 | -10.3% | -28.8% | -38.2% | |
| Q1 2022 | -5.5% | +5.3% | +28.7% | |
| Q4 2021 | +3.1% | -4.7% | -6.4% | |
| Q3 2021 | -2.2% | -6.6% | -30.0% | |
| Q2 2021 | -10.3% | -19.3% | +2.9% | |
| Q1 2021 | -15.3% | -8.2% | +11.4% | |
| Q4 2020 | +11.4% | +9.7% | -8.6% | |
| Q3 2020 | +19.7% | +112.7% | +106.3% | |
| Q2 2020 | -2.8% | -14.1% | -28.8% | |
| Q1 2020 | +14.6% | -1.7% | -12.3% | |
| Q4 2019 | -0.0% | -18.0% | -32.8% | |
| Q3 2019 | -2.4% | +0.6% | +0.6% | |
| Q2 2019 | +0.0% | +0.0% | +68.0% | |
| Q1 2019 | -2.0% | -6.9% | -7.8% | |
| Q4 2018 | +2.0% | +2.0% | -66.6% | |
| Q3 2018 | -7.5% | -8.6% | -15.5% | |
| Q2 2018 | -3.2% | -1.4% | +0.9% | |
| Q1 2018 | +0.0% | — | — | |
| Q4 2017 | +0.7% | — | — | |
| Q3 2017 | +7.0% | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro